PMX-60056: Phase Ib/II data

In an open label, dose-ranging Phase Ib/II trial in 12 healthy volunteers, PMX-60056 reversed the anticoagulant activity of heparin as measured by Activated Clotting Time (ACT). Specifically, ACT read...